A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT ID: NCT07192952

Last Updated: 2026-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-04-01

Study Completion Date

2030-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure with left ventricular systolic dysfunction (LVSD) is a condition where the left side of the heart is weak and struggles to pump blood effectively, leading to symptoms like shortness of breath, fatigue, and poor growth.

The study treatment, finerenone (also called BAY94-8862), is under development to treat newborns, children, and young adults with heart failure and LVSD. It works by blocking a protein that contributes to inflammation, scarring, and thickening in the heart and blood vessels, which may help the heart pump more blood effectively.

The main purpose of this study is to learn about how safe finerenone is and how well it works in the long-term treatment of heart failure and LVSD.

To understand how safe the treatment is, the study team will gather information on the number of patients who experience medical problems after taking finerenone, also known as "treatment emergent adverse events" (TEAEs). Additionally, they will collect blood samples to measure levels of an electrolyte called potassium and monitor blood pressure. They will also assess kidneys function using the estimated glomerular filtration rate (eGFR).

In this study, which is an extension of the earlier done FIORE study, finerenone will also be studied in newly enrolled newborns under 6 months with heart failure and LVSD and children and young adults from the FIORE study. The participants will be aged from newborns up to 18 years. All the participants will continue to receive their standard treatment as routine care for heart failure, along with finerenone during the study.

The participants will be in the study for around 10 to 11 months, depending on whether they rolled-over from the FIORE study or are newly enrolled newborns and infants \<6 months of age. They will take study treatment for up to 9 months. During this period, at least 6 visits are planned for participants. During these visits, the study team will:

* have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured
* have blood samples taken
* have physical examinations
* have their heart examined by an electrocardiogram and echocardiography
* answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answer
* for newborns and infants, evaluate the acceptability of the study drug formulation through parents or guardians' feedback.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

The doctors will check the participants' health a month after the participants take their last treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Left Ventricular Systolic Dysfunction Heart Failure (Pediatric)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Finerenone Open-Label Safety Extension

Participants will receive finerenone treatment.

Group Type EXPERIMENTAL

Finerenone (Kerendia, BAY94-8862)

Intervention Type DRUG

Finerenone in different doses, treatment duration will be 270±7 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Finerenone (Kerendia, BAY94-8862)

Finerenone in different doses, treatment duration will be 270±7 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For participants rolling over from randomized controlled trial (RCT): Prior participation in the finerenone Phase 3 study FIORE (21466) and not permanently discontinued from the study intervention prior to the end of treatment (EoT) visit in FIORE.
* For newly enrolled infants \<6 months of age: Left ventricular systolic dysfunction (LVSD) with left ventricular ejection fraction (LVEF) ≤ 50% at screening assessed by echocardiography.
* For newly enrolled infants \<6 months of age: Elevated NT-pro BNP levels (\> 500 mg/L) at screening.
* For newly enrolled infants \<6 months of age: Heart failure (HF) etiologies include congenital heart defects (CHD) with biventricular physiology and systemic LV; idiopathic cardiomyopathy (CM); familial/inherited and/or genetic CM; history of myocarditis (diagnosis of an acute episode at least 3 months prior to treatment assignment); neuromuscular disorder; inborn error of metabolism; mitochondrial disorder; acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional); ischemic (e.g., Kawasaki disease and postoperative HF); LV noncompaction.
* For newly enrolled infants \<6 months of age: Receiving standard of care (SoC) treatment for heart failure according to local guidelines or investigator´s discretion (on a stable regimen for 30 days before baseline).
* Newly enrolled newborns and infants \< 6 months of age must have a body weight of ≥3 kg at Visit 1.

Exclusion Criteria

* For participants rolling over from randomized controlled trial (RCT): To roll-over to FIORELLO, all participants: Potassium (K+) \>5.5 mmol/L. After unblinding:

* For participants who received finerenone in FIORE: K+ \>5.5 mmol/ L
* For participants who received placebo in FIORE: K+ \>5.0 mmol/L for children ≥2 years of age, and \>5.3 mmol/L for children \<2 years of age (if eGFR is \<60 mL/min/1.73m² for participants \<2 years of age, the serum potassium threshold of \>5.0 mmol/L will be used for exclusion)
* For newly enrolled newborns and infants \< 6 months of age: Potassium ≥ 5.3 mmol/l (if eGFR is \<60 mL/min/1.73m², the serum potassium threshold of \>5.0 mmol/L will be used for exclusion).
* For participants rolling over from RCT: Severe renal dysfunction with estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² at FIORE EoT or Visit 1.
* For newly enrolled infants \< 6 months of age: Severe renal dysfunction with eGFR \< 30 ml/min/1.73m2 at screening or Visit 1.
* Treatment with a mineralocorticoid receptor antagonist, other than the study intervention, (e.g., spironolactone, eplerenone) within 30 days of Visit 1.
* Requirement of any intravenous (IV) vasoactive agents; mechanical ventilation; mechanical circulatory support; sustained or symptomatic arrhythmias not controlled by drug or device therapy within 30 days prior to study treatment.
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital Colorado - Anschutz Medical Campus - Cardiology

Aurora, Colorado, United States

Site Status

Nemours Children's Hospital - Delaware - Cardiology

Wilmington, Delaware, United States

Site Status

UF Health Shands Hospital - Pediatric Cardiology

Gainesville, Florida, United States

Site Status

Joe Dimaggio Children's Hospital - Cardiology

Hollywood, Florida, United States

Site Status

Emory University Hospital - Children's Healthcare of Atlanta Cardiology - Atlanta

Atlanta, Georgia, United States

Site Status

Riley Hospital For Children - Cardiology

Indianapolis, Indiana, United States

Site Status

Boston Children's Hospital - Main Campus - Cardiology

Boston, Massachusetts, United States

Site Status

C.S. Mott Children's Hospital - Cardiology

Ann Arbor, Michigan, United States

Site Status

Children's Mercy Hospital Kansas City - Cardiology

Kansas City, Missouri, United States

Site Status

Washington University - St. Louis Children's Hospital - Cardiology

St Louis, Missouri, United States

Site Status

Icahn School of Medicine at Mount Sinai - Pediatric Cardiology

New York, New York, United States

Site Status

Columbia University Irving Medical Center - Pediatric Cardiology

New York, New York, United States

Site Status

The Children's Hospital at Montefiore - Cardiology

The Bronx, New York, United States

Site Status

Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic Children's

Cleveland, Ohio, United States

Site Status

Nationwide Children's Hospital - Cardiology

Columbus, Ohio, United States

Site Status

Children's Hospital of Philadelphia - Cardiology

Philadelphia, Pennsylvania, United States

Site Status

UPMC Children's Hospital of Pittsburgh - Cardiology

Pittsburgh, Pennsylvania, United States

Site Status

MUSC Shawn Jenkins Children's Hospital - Cardiology

North Charleston, South Carolina, United States

Site Status

Children's Medical Center Dallas - Cardiology

Dallas, Texas, United States

Site Status

Texas Children's Hospital - Cardiology

Houston, Texas, United States

Site Status

Eccles Primary Children's Outpatient Services - Cardiology

Salt Lake City, Utah, United States

Site Status

Hospital de Niños Sor María Ludovica

La Plata, Buenos Aires, Argentina

Site Status

Instituto De Investigaciones Clinicas Zarate | Zarate, Argentina

Zárate, Buenos Aires, Argentina

Site Status

Consultorios Integrados Rosario | Instituto Medico de la Fundacion de Estudios Clinicos

Rosario, Santa Fe Province, Argentina

Site Status

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Site Status

Hospital de Pediatría Juan P. Garrahan

Buenos Aires, , Argentina

Site Status

Hospital General de Ninos Pedro de Elizalde | Nephrology Department

Buenos Aires, , Argentina

Site Status

Hospital General de Ninos Ricardo Gutierrez | Pediatric Nephrology Department

Ciudad Autónoma de Buenos Aire, , Argentina

Site Status

Consultorios Médicos Dr. Doreski

Ciudad Autónoma de Buenos Aire, , Argentina

Site Status

Sanatorio de la Cañada

Córdoba, , Argentina

Site Status

Centro Cardiovascular Salta (Torzav SRL)

Salta, , Argentina

Site Status

Kepler Universitätsklinikum GmbH - Klinik für Kinderkardiologie

Linz, , Austria

Site Status

Medizinische Universität Wien - Klinik für Kinder- und Jugendheilkunde, Abteilung für Pädiatrische Kardiologie

Vienna, , Austria

Site Status

UZ Leuven - Pediatric Cardiology

Leuven, Flemish Brabant, Belgium

Site Status

Cliniques Universitaires St-Luc (UCL) - Pediatric Cardiology

Brussels, , Belgium

Site Status

UZ Antwerpen - Pediatric Cardiology

Edegem, , Belgium

Site Status

UZ Gent - Pediatric Cardiology

Ghent, , Belgium

Site Status

CHC MontLegia - Pediatric Cardiology

Liège, , Belgium

Site Status

IESG - Instituto de Ensino da Saude e Gestao

Salvador, Estado de Bahia, Brazil

Site Status

Santa Casa de Misericórdia de Belo Horizonte

Belo Horizonte, Minas Gerais, Brazil

Site Status

Hospital de Clínicas da Universidade Federal de Uberlândia Empresa Brasileira de Serviços Hospitalares - EBSERH

Uberlândia, Minas Gerais, Brazil

Site Status

Hospital Pequeno Principe

Curitiba, Paraná, Brazil

Site Status

Fundação Universidade de Caxias do Sul

Caxias do Sul, Rio Grande do Sul, Brazil

Site Status

Centro de Pesquisa Clinica e Populacional Hospitalize

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Campinas Clinical Research Institute (IPECC) | Campinas, Brazil

Campinas, São Paulo, Brazil

Site Status

Hospital Infantil Sabará - Instituto PENSI - Pesquisa e Ensino em Saúde Infantil

São Paulo, São Paulo, Brazil

Site Status

Instituto Dante Pazzanese de Cardiologia | Divisao de Pesquisa

São Paulo, São Paulo, Brazil

Site Status

InCor HCFMUSP

São Paulo, São Paulo, Brazil

Site Status

National Heart Hospital (NHH) - Dept. Pediatric Cardiology

Sofia, Sofia, Bulgaria

Site Status

University Multiprofile Hospital for Active Treatment 'Sveti Georgi' EAD, Plovdiv Pediatric Clinic

Plovdiv, , Bulgaria

Site Status

Medical Center Nora- Heart ?OOD Child Cardiology

Sofia, , Bulgaria

Site Status

University Multiprofile Hospital for Active Treatment 'Sveta Ekaterina' EAD, Sofia

Sofia, , Bulgaria

Site Status

BC Children's Hospital - Children's Heart Centre

Vancouver, British Columbia, Canada

Site Status

London Health Sciences Centre - Children's Hospital

London, Ontario, Canada

Site Status

The Hospital for Sick Children (SickKids)

Toronto, Ontario, Canada

Site Status

CHU Sainte-Justine

Montreal, Quebec, Canada

Site Status

University of Saskatchewan, Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Fakultní nemocnice Brno, Detská nemocnice - Pediatrická klinika

Brno, , Czechia

Site Status

Fakultní nemocnice v Motole - Detské kardiocentrum 2. LF UK a FN Motol

Prague, , Czechia

Site Status

HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Uusi lastensairaala, kardiologia

Helsinki, , Finland

Site Status

Universitaetsklinikum Giessen und Marburg GmbH - Kinderherzzentrum und Zentrum für angeborene Herzfehler

Giessen, Hesse, Germany

Site Status

Universitätsklinikum Köln - Kinderkardiologie

Cologne, , Germany

Site Status

Universitätsklinikum Tübingen, Kinderheilkunde II - Kinderkardiologie, Pulmologie, Intensivmedizin

Tübingen, , Germany

Site Status

Athens General Children's Hospital Panagioti And Aglaia Kyriakou -2nd University Department of Pediatrics

Athens, , Greece

Site Status

Athens General Children's Hospital Panagioti And Aglaia Kyriakou, Cardiology Department

Athens, , Greece

Site Status

Nosokomeio Paidon I Agia Sofia, Cardiology Department

Athens, , Greece

Site Status

Onassis Cardiac Surgery Center, Department of Pediatric Cardiology and Adult Congenital Heart Disease

Kalithèa, , Greece

Site Status

Gottsegen Gyorgy Orszagos Kardiovaszkularis Intezet - Gyermeksziv Kozpont

Budapest, , Hungary

Site Status

Rambam Health Corporation

Haifa, , Israel

Site Status

Edith Wolfson Medical Center (EWMC)

Holon, , Israel

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Dana-Dwek Children's Hospital

Tel Aviv, , Israel

Site Status

Chaim Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 2 - Cardiopatie Congenite del bambino e dell'adulto

Bergamo, , Italy

Site Status

Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico Sant'Orsola-Cardiologia pediatrica ed dell'età evolutiva

Bologna, , Italy

Site Status

IRCCS Istituto Giannina Gaslini - Cardiologia

Genova, , Italy

Site Status

ASST Grande Ospedale Metropolitano Niguarda - Struttura semplice dipartimentale cardiologia pediatrica

Milan, , Italy

Site Status

Azienda Ospedaliera Dei Colli_Monaldi - Malattie Rare e Genetiche Cardiovascolari

Naples, , Italy

Site Status

Azienda Ospedale-Università di Padova - UOC Cardiologia Pediatrica

Padua, , Italy

Site Status

Ospedale Pediatrico Bambino Gesù - Unità Terapie Cardiovascolari Avanzate

Roma, , Italy

Site Status

A.O.U. Città della Salute e della Scienza di Torino_Regina Margherita - Cadiologia pediatrica

Torino, , Italy

Site Status

Centro de Investigación Clínica Médica y Farmacológica S.A de C.V

Guadalajara, Jalisco, Mexico

Site Status

Hospital Infantil de México "Dr. Federico Gómez"

Mexico City, Mexico City, Mexico

Site Status

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Pediatria

Monterrey, Nuevo León, Mexico

Site Status

Hospital Angeles (HA)-Lomas

Huixquilucan, State of Mexico, Mexico

Site Status

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares

Ciudad Madero, Tamaulipas, Mexico

Site Status

Centro de Estudios Clínicos de Querétaro S.C.

Querétaro, , Mexico

Site Status

Centro de Atención e Investigación Cardiovascular del Potosí S.C.

San Luis Potosí City, , Mexico

Site Status

Instituto Nacional de Cardiología "Ignacio Chávez"

Tlalpan, , Mexico

Site Status

Pomnik Centrum Zdrowia Dziecka - Klinika Kardiologii

Warsaw, Masovian Voivodeship, Poland

Site Status

Górnoslaskie Centrum Zdrowia Dziecka im. sw. Jana Pawla II SPSK Nr 6 Slaskiego UM w Katowicach - Oddzial Kardiologii Dzieciecej

Katowice, , Poland

Site Status

Instytut Centrum Zdrowia Matki Polki w Lodzi - Klinika Kardiologii

Lódz, , Poland

Site Status

Wojewódzki Szpital Specjalistyczny we Wroclawiu Osrodek Badawczo-Rozwojowy Oddzial Kardiologii Dzieciecej

Wroclaw, , Poland

Site Status

Department of Cardiology - Research Unit

Coimbra, , Portugal

Site Status

Hospital Santa Marta | Pediatric Cardiology Department

Lisbon, , Portugal

Site Status

Hospital de Santa Cruz | Pediatric Cardiology Department

Lisbon, , Portugal

Site Status

Centro Materno infantil do Norte - Pediatric Cardiology

Porto, , Portugal

Site Status

ULS São João - Pediatric Department

Porto, , Portugal

Site Status

Pusan National University Yangsan Children's Hospital

Yangsan, Gyeongsangnam-do, South Korea

Site Status

Seoul National University Hospital-Pediatrics Department

Jongno, Seoul, South Korea

Site Status

Severance Hospital, Yonsei University Health System-Pediatrics Department

Seodaemun, , South Korea

Site Status

Samsung Medical Center-Pediatrics

Seoul, , South Korea

Site Status

Hospital Sant Joan De Deu Barcelona | Cardiologia pediatrica

Esplugues de Llobregat, Barcelona, Spain

Site Status

Hospital Universitari Vall D Hebron | Cardiologia pediatrica

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia | Cardiologia pediatrica

Córdoba, , Spain

Site Status

Hospital Universitario Ramon Y Cajal | Cardiologia pediatrica

Madrid, , Spain

Site Status

Hospital Universitario 12 De Octubre | Cardiologia pediatrica

Madrid, , Spain

Site Status

Hospital Universitario La Paz | Cardiologia pediatrica

Madrid, , Spain

Site Status

Hospital Universitario Regional De Malaga | Cardiologia pediatrica

Málaga, , Spain

Site Status

Hospital Universitario Virgen Del Rocio S.L. | Cardiologia pediatrica

Seville, , Spain

Site Status

Skånes Universitetssjukhus Lund - Barnhjärtcentrum

Lund, Skåne County, Sweden

Site Status

Chang Gung Memorial Hospital (CGMH) - Kaohsiung Branch

Guishan, , Taiwan

Site Status

Kaohsiung Veterans General Hospital

Kaohsiung City, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

MacKay Children's hospital

Taipei, , Taiwan

Site Status

Cukurova Universitesi Tip Fakultesi Hastanesi

Adana, , Turkey (Türkiye)

Site Status

Hacettepe Universitesi Tip Fakultesi

Ankara, , Turkey (Türkiye)

Site Status

Ankara Bilkent Sehir Hastanesi

Bilkent Ankara, , Turkey (Türkiye)

Site Status

Marmara Uni. Tip Fak. Pendik EAH Kardiyoloji

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul Mehmet Akif Ersoy Gogus Kalp Damar Cerrahisi E.A.H.

Istanbul, , Turkey (Türkiye)

Site Status

Izmir Dr. Behcet Uz Cocuk Hastaliklari Hast

Izmir, , Turkey (Türkiye)

Site Status

University Hospitals of Leicester NHS Trust | Leicester Children's Hospital - Children's Research Facility

Leicester, Leicestershire, United Kingdom

Site Status

Alder Hey Children's NHS Foundation Trust | Alder Hey Children's Hospital - Clinical Research Facility

Liverpool, Merseyside, United Kingdom

Site Status

Belfast Health and Social Care Trust | Royal Belfast Hospital for Sick Children - Paediatric Cardiology

Belfast, Northern Ireland, United Kingdom

Site Status

NHS Greater Glasgow and Clyde | Royal Hospital for Children - Glasgow Clinical Research Facility

Glasgow, Scotland, United Kingdom

Site Status

Newcastle upon Tyne Hospitals NHS Foundation Trust |Freeman Hospital - Children's Heart Unit

Newcastle upon Tyne, Tyne and Wear, United Kingdom

Site Status

Leeds Teaching Hospitals NHS Trust | Leeds Children's Hospital - Children's Research Facility

Leeds, West Yorkshire, United Kingdom

Site Status

University Hospitals Bristol and Weston NHS Foundation Trust | Bristol Royal Hospital for Children - Clinical Research Facility

Bristol, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Austria Belgium Brazil Bulgaria Canada Czechia Finland Germany Greece Hungary Israel Italy Mexico Poland Portugal South Korea Spain Sweden Taiwan Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bayer Clinical Trials Contact

Role: CONTACT

(+)1-888-84 22937

Related Links

Access external resources that provide additional context or updates about the study.

https://clinicaltrials.bayer.com/

Click here to find further information and, after study completion, the study results according to Bayer's transparency standards.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-519830-22-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

21467

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Finerenone and Cardiac Remodeling
NCT07270367 NOT_YET_RECRUITING PHASE3